The EIT Health Startups Meet Pharma is a challenge-based acceleration program connecting startups developing innovative solutions for chronic care with key pharma partners in Europe. The program had its premiere in 2019 with 14 healthcare startups from all over Europe that tackled five different challenges set up by EIT Health Partners Amgen, Bayer, Ferrer, Janssen and UCB. Read more about the 2019 edition.
In 2020, five challenges have been released in collaboration with four EIT Health Partners: Amgen, Bayer, Beiersdorf and Boehringer Ingelheim.
Programme structure
Module 1 (June 29-July 3, Heidelberg) : 5 days “Innovation & Entrepreneurship training”. Startups receive tailored workshops by pharma experts on the different tools and methods to successfully build their business.
Module 2 (July 15-25 in Heidelberg) : 5 days workshops by pharma partners on how to collaborate with big players in the market.
Module 3 (September 2020): Startups visit selected pharma companies to discuss collaboration opportunities.
Module 4 (November 2020 – date & location TBD) : Demo Day. Startups pitch their achievements in front of Investors and EIT Health stakeholders.
Gold sponsors:
Silver sponsor:
Pharma company: Amgen
Title: Encourage continuity in treatment strategy and treatment optimization for post-myocardial infarction patients
Disease Area: Cardiology
Looking for: a) a predictive analytic tool to identify very high risk patients & b) a procedure/tool which will provide a holistic support to post-MI patients after discharge.
Pharma company: Amgen
Title: Choosing the right treatment for Multiple Myeloma patients
Disease area: Multiple Myeloma
Looking for:Creation of an algorithm, that would help physicians choosing the right treatment for Multiple Myeloma patients
Pharma company: Bayer AG
Title: Disruptive Gene therapies, cell therapies and delivery technologies for different therapeutic areas
Disease Area: Cardiology, Oncology, Gynecology, Ophthalmology, Hematology and Women’s Health
Looking for: Disruptive technologies useful in the therapeutic areas of Cardiology, Oncology, Gynecology, Ophthalmology, Hematology and Women’s Health – or ideally for all of those as a platform technology. Breakthrough innovations for other or multiple indications might be of interest as well.
Pharma company: Boehringer Ingelheim
Title: Portable Interstitial Lung Disease (ILD) Diagnostic Tool
Disease Area: Interstitial Lung Diseases
Looking for: Portable Interstitial Lung Disease (ILD) Diagnostic Tool
Pharma company: Beiersdorf AG
Title: Improving the condition of diabetic skin
Disease Area: Diabetes, Skin
Looking for: BioTech, MedTech or Digital Health solutions to improve the condition of diabetic skin